De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

GSK Dividend

Dividend criteriumcontroles 3/6

GSK is een dividendbetalend bedrijf met een huidig rendement van 3.81% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

4.0%

Dividendrendement

60%

Uitbetalingsratio

Gemiddelde opbrengst industrie	2.3%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	UK£0.580
Winst per aandeel	UK£0.99
Dividendrendementsvoorspelling	4.7%

Recente dividendupdates

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Aug 05

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: De dividendbetalingen van GSK zijn de afgelopen 10 jaar volatiel geweest.

Groeiend dividend: De dividendbetalingen van GSK zijn de afgelopen 10 jaar gedaald.

Dividendrendement versus markt

GSK Dividendrendement versus markt

Hoe verhoudt GSK dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (GSK)	4.0%
Markt onderkant 25% (GB)	2.1%
Markt Top 25% (GB)	5.6%
Gemiddelde industrie (Pharmaceuticals)	2.3%
Analist prognose (GSK) (tot 3 jaar)	4.7%

Opmerkelijk dividend: Het dividend van GSK ( 3.81% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de UK markt ( 2.08% ).

Hoog dividend: Het dividend GSK ( 3.81% ) is laag vergeleken met de top 25% van dividendbetalers in de UK markt ( 5.53% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn redelijke payout ratio ( 60.5% ) worden de dividendbetalingen van GSK gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijk lage cash payout ratio ( 45.3% ) worden de dividendbetalingen van GSK goed gedekt door de kasstromen.

GSK Dividend

Dividend criteriumcontroles 3/6

Belangrijke informatie

Recente dividendupdates

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK (LON:GSK) Will Pay A Dividend Of £0.15

Recent updates

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend